AI successfully used for prostate cancer treatment
- September 03, 2018
A research team led by Prof. Dean Ho – Director of Singapore Institute for Neurotechnology (SINAPSE) and BIGHEART faculty – has successfully treated a prostate cancer patient using the CURATE.AI artificial intelligence platform to optimise the effectiveness of combination drug treatment.
“Dynamic dosing in cancer therapy is not commonly used. In fact, drug dosing changes in oncology are typically performed only to reduce toxicity. CURATE.AI uniquely modifies drug dosing to increase efficacy. Our clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment. A patient’s clinical profile changes over time. The unique ability for CURATE.AI to rapidly identify the drug doses that result in the best possible treatment outcomes allows for actionable, and perpetually optimised personalised medicine,” Prof. Ho said.
Aside from cancer treatment, CURATE.AI platform has other potential applications such as prevention of transplant rejection, cardiovascular medicine, diabetes management and treatment of infectious diseases.
Please click the link below for the research article:
Please click the links below for the news articles:
